The introduction of targeted therapies into clinical practice paved the way for personalized medicine and improvements in the efficacy of cancer treatment but resistance remains a problem and has been reported in many studies, including those conducted with ALK TKIs2–4,41. This evidence concerns the gene ALK and cancer.